Hepatocellular Carcinoma Clinical Trials

64 studies are recruiting for hepatocellular carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

   This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT04472767 on ClinicalTrials.gov

2. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

   Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Dan Zandberg

   See if you can join NCT04114136 on ClinicalTrials.gov

3. A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

   To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07116486 on ClinicalTrials.gov

4. Y-90 Treatment Response Using Transarterial Radioembolization

   This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07145801 on ClinicalTrials.gov

5. Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

   This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT06265285 on ClinicalTrials.gov

6. Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

   The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   7 in total

   Run by

   Northwestern University

   See if you can join NCT05620771 on ClinicalTrials.gov

7. Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

   This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies…

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Locations

   2 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT05468359 on ClinicalTrials.gov

8. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

   Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06503146 on ClinicalTrials.gov

9. 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

   The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio

   Run by

   Melissa Lumish

   See if you can join NCT06852820 on ClinicalTrials.gov

10. A Study of ZW251 in Participants With Advanced Solid Tumors

    The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Comprehensive Cancer Center, San Francisco, California

    Locations

    25 in total

    Run by

    Zymeworks BC Inc.

    See if you can join NCT07164313 on ClinicalTrials.gov

11. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

    The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama

    Locations

    21 in total

    Run by

    Tvardi Therapeutics, Incorporated

    See if you can join NCT05440708 on ClinicalTrials.gov

12. Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

    This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapa…

    Stage

    Phase 1

    Ages

    20 to 99

    Site

    Stanford University, Palo Alto, California

    Locations

    2 in total

    Run by

    Teclison Ltd.

    See if you can join NCT02174549 on ClinicalTrials.gov

13. Combination of TATE and PD-1 Inhibitor in Liver Cancer

    This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellula…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    University of California, Irvine, Orange, California

    Locations

    3 in total

    Run by

    Teclison Ltd.

    See if you can join NCT03259867 on ClinicalTrials.gov

14. Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

    Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania

    Run by

    VA Office of Research and Development

    See if you can join NCT05842174 on ClinicalTrials.gov

15. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Diwakar Davar

    See if you can join NCT07223424 on ClinicalTrials.gov

16. Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

    This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and …

    Stage

    Not phased

    Ages

    Any age

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05143619 on ClinicalTrials.gov

17. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Cancer Center, Aurora, Colorado

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

18. GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

    Background: A new cancer treatment takes a person s own T cells, modifies them in a laboratory so they can better fight cancer cells, and then gives them back to the person. Researchers want to see if this treatment can help people with a certain types of cancer. Objective: To see if a personalized…

    Stage

    Phase 1

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05003895 on ClinicalTrials.gov

19. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

    The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    12 in total

    Run by

    Replimune, Inc.

    See if you can join NCT05733598 on ClinicalTrials.gov

20. Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

    This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06553885 on ClinicalTrials.gov

21. A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

    Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rogel Comprehensive Cancer Center, Ann Arbor, Michigan

    Run by

    University of Michigan Rogel Cancer Center

    See if you can join NCT05901519 on ClinicalTrials.gov

22. Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

    This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment stra…

    Stage

    Not phased

    Ages

    Any age

    Site

    The Ohio State University Wexner Medical Center, Columbus, Ohio

    Run by

    Mohamed Abdel-Rahman

    See if you can join NCT04792463 on ClinicalTrials.gov

23. SBRT With Atezo/Bev for HCC

    A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT05488522 on ClinicalTrials.gov

24. Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

    This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived fr…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT07148050 on ClinicalTrials.gov

25. Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

    This study evaluates barriers to early detection of liver cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    USC / Norris Comprehensive Cancer Center, Los Angeles, California

    Run by

    University of Southern California

    See if you can join NCT07312162 on ClinicalTrials.gov